Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06702332 | Single Ascending Dose Study of MSD-001 in Healthy Participants | PHASE1 | COMPLETED | 47 | — | — | Nov 11, 2024 | Jul 11, 2025 | Sep 16, 2025 | 1 | Netherlands |
Treatment emergent adverse events/ treatment emergent serious adverse events - their frequency, duration and severity, clinically significant changes in lab parameters, ECG, and vital signs
| Arm | Type | Description |
|---|---|---|
| Active Treatment: MSD-001 | ACTIVE_COMPARATOR | Planned doses of MSD-001; N = 42 |
| Placebo Comparator | PLACEBO_COMPARATOR | Non-active study drug N = 10 |
| Name | Type | Description |
|---|---|---|
| MSD-001 | DRUG | MSD-001 is being developed as part of future two-agent combination treatment approaches for the management of mental health indications |
| Placebo Comparator | DRUG | Matching Placebo |
Key Inclusion Criteria: * Male or female healthy consented participants 18 to 55 years of age * CYP2D6 phenotype established based on pharmacogenetic testing. * Free from psychoactive drug use from 4 weeks before dosing and until the last follow up visit. Key Exclusion Criteria: * Any current cli...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Teladoc Health, Inc. | TDOC | 1 | NA | Undisclosed |
| Unity Health Toronto | UBX | 2 | NA | Undisclosed |